Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
The Food and Drug Administration (FDA) is amending certain regulations as the first phase of an incremental approach to modifying the current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. We are amending the regulations to modernize or clarify some of the CGMP requirements, as well as harmonize some of the CGMP requirements with those of other foreign regulators and other FDA regulations. These amendments are also consistent with current industry practice. We are taking this action as part of our continuing effort to revise outdated regulations without diminishing public health protection. We are issuing a direct final rule for this action because FDA expects there will be no significant adverse comments on these amendments. Elsewhere in this issue of the Federal Register, we are publishing a companion proposed rule, under our usual notice-and-comment rulemaking procedures, to provide a procedural framework to finalize the rule in the event the agency receives any significant adverse comments and withdraws this direct final rule. The companion proposed rule and direct final rule are substantively identical.
D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence* / Q000592:standards; D003257:Consumer Product Safety / Q000331:legislation & jurisprudence / Q000592:standards; D004345:Drug Industry / Q000331:legislation & jurisprudence* / Q000592:standards; D005161:Facility Regulation and Control / Q000331:legislation & jurisprudence / Q000592:standards; D006801:Humans; D011786:Quality Control; D014481:United States; D014486:United States Food and Drug Administration